1 year return (CAGR)
2828.79%
Active Biotech AB Exchange (ST, SEK)
ACTI.ST
3.79
-0.13 (-3.16%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
143.69%
5 year return (CAGR)
53.97%
10 year return (CAGR)
5.00%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
100.83M
Price/Sales
-
Ent value
67.63M
Price/Book
2.71
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-16.59%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 3.90 |
| Daily high | 4.04 |
| Daily low | 3.83 |
| Daily Volume | 36K |
| All-time high | 103.64 |
| 1y analyst estimate | 25.00 |
| Beta | 1.34 |
| EPS (TTM) | -1.27 |
| Dividend per share | 0.00 |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 7 May 2026 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -96.34% | -1.06% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 18 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -92.38% | -10.67% |
| Avg time to new high | 3724 days | 12 days |
| Max time to new high | 7446 days | 1805 days |
News
NKT now sits against an updated fair value of DKK 952.88 compared with DKK 915.46 previously, which places the internal pricing anchor closer to the DKK 895 to DKK 917 range used in recent Street targ...
October 3, 2026
Tecan Group is back in focus after analysts lifted their fair value estimate from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Several firms have adjusted targets...
October 3, 2026
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S
October 2, 2026
In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
October 2, 2026
AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
October 2, 2026
Abogen Biosciences ("Abogen" or the "Group"), a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis to advan...
October 2, 2026
Suominen Corporation's stock exchange release on October 1, 2026, at 3:15 p.m. (EEST) Suominen Corporation (hereinafter the “Company”) has transferred without consideration a total of 324,000 of Compa...
October 1, 2026